Celldex Therapeutics’ $150 Million Common Stock Offering


Lowenstein Sandler represented issuer Celldex Therapeutics, Inc. in the offering.

Celldex Therapeutics, Inc. (Celldex) (Nasdaq: CLDX) completed a $150 million public offering of common stock underwritten by Cantor Fitzgerald & Co. as sole book-running manager and H.C. Wainwright & Co. acting as co-manager for the offering.

Celldex is a biopharmaceutical company focused on the development and commercialization of immunotherapies and other targeted biologics.

The Lowenstein team advising Celldex Therapeutics included Anthony O. Pergola (Picture), Alan Wovsaniker, Kate Basmagian, Alexander Dinur, Madeline Roe, Sarah Gore, and Robert J. Paradiso.

Involved fees earner: Kate Basmagian – Lowenstein Sandler LLP; Alexander Dinur – Lowenstein Sandler LLP; Sarah Gore – Lowenstein Sandler LLP; Robert Paradiso – Lowenstein Sandler LLP; Anthony Pergola – Lowenstein Sandler LLP; Madeline Roe – Lowenstein Sandler LLP; Alan Wovsaniker – Lowenstein Sandler LLP;

Law Firms: Lowenstein Sandler LLP;

Clients: Celldex Therapeutics;

Author: Ambrogio Visconti